Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial
Akihiko Koshino,Megumi Oda,Clare Arnott,Robert A. Fletcher,George L. Bakris,Meg Jardine,Kenneth W. Mahaffey,Vlado Perkovic,Carol A. Pollock,Hiddo J.L. Heerspink,Brendon L. Neuen